Search Results
Nov 10, 2025, 08:45 ET Novo Nordisk's Wegovy® (semaglutide 2.4 mg) was associated with liver health-related benefits not solely based on weight loss in adult patients with MASH with liver scarring, according to a new post hoc analysis
A, Mezzabotta L, Bugianesi E. Systemic complications of nonalcoholic fatty liver disease: when the liver is not an innocent bystander. Semin Liver Dis. 2015;35(3):236-249.
More news about: NOVO NORDISK INC.
Nov 07, 2025, 19:29 ET U.S. FDA approves KYGEVVI™ (doxecitine and doxribtimine), the first and only treatment for adults and children living with thymidine kinase 2 deficiency (TK2d)
Berardo A, et al. Advances in Thymidine Kinase 2 Deficiency: Clinical Aspects, Translational Progress, and Emerging Therapies. J Neuromuscul Dis. 2022;9(2):225-235. Wang J, et al. eds. GeneReviews®. [Internet]. Seattle (WA): University of Washington, Seattle; 1993-2024.
More news about: UCB
Nov 07, 2025, 11:51 ET Les déficits immunitaires secondaires au centre des débats à l'IPIC 2025 : Kedrion défend l'innovation et les soins aux patients
extrêmement précieuse pour répondre aux besoins des patients atteints de DIS. Une collaboration plus étroite est maintenant nécessaire pour impliquer de nouveaux experts médicaux, notamment les hématologues qui prennent en charge les DIS, pour établir des liens avec ceux qui traitent les DIP, en vue d'améliorer
More news about: Kedrion
Nov 06, 2025, 21:00 ET Argo Biopharma to Present Positive Phase I Results of siRNA Therapeutic BW-20805 for HAE at ACAAI 2025
Pedro Giavina-Bianchi, et al. CLINICS (2011); 66(9):1627-1636 Aygören-Pürsün, E., et al. (2018). Orphanet J Rare Dis 13(1): 73.
More news about: Argo Biopharmaceutical Co., Ltd
Nov 05, 2025, 06:00 ET Maple Leaf Foods Reports Third Quarter 2025 Financial Results
expectations and assumptions concerning the spin-off, including the implications of the risks, benefits, costs, dis-synergies, and tax structure; the impact of the operationalization of the agreements between the Company and Canada Packers; and the Company's ability to
More news about: Maple Leaf Foods Inc.
Nov 04, 2025, 06:50 ET BD Achieves Milestone in AGILITY Study of Revello™ Vascular Covered Stent for Treatment of Peripheral Artery Disease
1 Yost M. The current U.S. prevalence of peripheral arterial disease. Vasc Dis Manag. 2023;20(4):E67-E73.2 Allison MA, Armstrong DG, Goodney PP, et al. Health disparities in peripheral artery disease: A scientific
More news about: BD (Becton, Dickinson and Company)
Oct 31, 2025, 13:04 ET BIMZELX® (bimekizumab-bkzx) Data in Hidradenitis Suppurativa Showed Improvements in Pain and Resolution of Draining Tunnels Sustained to Three Years
[abstract]. Skin. 2024,8(6):s473. EADV. 7925. Sabat R, Jemec GBE, Matusiak L, et al. Hidradenitis suppurativa. Nat Rev Dis Primers. 2020;6(1):18. Jemec GBE. Clinical practice. Hidradenitis suppurativa. N Engl J Med. 2012;366(2):158–64.
More news about: UCB
Oct 29, 2025, 08:05 ET Johnson & Johnson announces first head-to-head study comparing IMAAVY™ with an alternative FcRn blocker in generalized myasthenia gravis (gMG) at AANEM Annual Meeting
14 Finnis MF, Jayawant S. Juvenile myasthenia gravis: a paediatric perspective. Autoimmune Dis. 2011;2011:404101. doi: 10.4061/2011/404101.
More news about: Johnson & Johnson
Oct 29, 2025, 07:00 ET UCB to unveil new data for RYSTIGGO® (rozanolixizumab-noli) and ZILBRYSQ®(zilucoplan) for gMG at the 2025 AANEM Annual Meeting and MGFA Scientific Session
https://myasthenia.org/understanding-mg/overview-mg/. Accessed October 2025.11. Juel VC, Massey JM. Myasthenia Gravis. Orphanet J Rare Dis. 2007;2:44.12. Bril V. Safety and efficacy of rozanolixizumab in patients with generalised myasthenia gravis: a randomised, double-blind, placebo-controlled,
More news about: UCB
Oct 28, 2025, 08:00 ET Novo Nordisk to present new Wegovy® (semaglutide 2.4 mg) data at the 2025 American Association for the Study of Liver Diseases annual meeting
Mezzabotta L, et al. Systemic Complications of Nonalcoholic Fatty Liver Disease: When the Liver Is Not an Innocent Bystander. Semin Liver Dis. 2015;35:236-49. Ekstedt M, Hagstrom H, Nasr P, et al. Fibrosis stage is the strongest predictor for disease-specific
More news about: NOVO NORDISK INC.
Oct 28, 2025, 08:00 ET Novo Nordisk to present new Wegovy® (semaglutide 2.4 mg) data at the 2025 American Association for the Study of Liver Diseases annual meeting
Mezzabotta L, et al. Systemic Complications of Nonalcoholic Fatty Liver Disease: When the Liver Is Not an Innocent Bystander. Semin Liver Dis. 2015;35:236-49. Ekstedt M, Hagstrom H, Nasr P, et al. Fibrosis stage is the strongest predictor for disease-specific
More news about: NOVO NORDISK INC.
Oct 27, 2025, 09:15 ET Dimensional Innovations Releases Exhibit Details for Theodore Roosevelt Presidential Library
hills of the surrounding Badlands region. It also reflects Roosevelt's love of nature, and his role in expanding the country's National Park System. DI's fabrication work also adheres to the facility's goal of achieving "
More news about: Dimensional Innovations
Oct 27, 2025, 07:18 ET KDP Discusses Strategy, Leadership and Financing for Upcoming Transformational Transactions
include establishing optimal operating models, executing a seamless integration, driving cost synergy capture and offsets to any separation-related dis-synergies, and setting up for a successful separation. Webcast Information
More news about: Keurig Dr Pepper
Oct 25, 2025, 11:00 ET BIMZELX® (bimekizumab-bkzx) Three-Year Rheumatology Data at ACR 2025 Demonstrated Sustained Inflammation Control in Psoriatic Arthritis and Axial Spondyloarthritis
in adults: a review. JAMA. 2025;334(5):419-434. Ogdie A, Weiss P. The Epidemiology of Psoriatic Arthritis. Rheum Dis Clin North Am. 2015;41(4):545–68. Mease PJ, Gladman DD, Papp KA, et al. Prevalence of rheumatologist-diagnosed psoriatic
More news about: UCB
Oct 23, 2025, 14:00 ET Destinations International Sets Course for Destination Leadership at 2025 Advocacy Summit
new model for destination advocacy that goes beyond communication to embed advocacy across governance, strategy and performance. The report draws from DI's ongoing DestinationNEXT Futures Study, which found that 42% of destination organizations anticipate funding reductions within three years, underscoring
More news about: Destinations International
Oct 21, 2025, 06:30 ET 3M Delivers Strong Third-Quarter Results; Increases Full-Year Margin and EPS Guidance
to the spin-off of the Company's Health Care business, including the risk that the expected benefits will not be realized; the risk that the costs or dis-synergies will exceed the anticipated amounts; potential impacts on the Company's relationships with its customers, suppliers, employees, regulators
More news about: 3M Company
Oct 20, 2025, 09:00 ET RedHill's Talicia® Secures $4 Million Strategic Investment and U.S. Co-Commercialization Partnership Deal
(SEER). 9 Malfertheiner, P., Camargo, M.C., El-Omar, E. et al. Helicobacter pylori infection. Nat Rev Dis Primers 9, 19 (2023). https://doi.org/10.1038/s41572-023-00431-8
More news about: RedHill Biopharma Ltd.
Oct 20, 2025, 08:00 ET RINVOQ® (upadacitinib) Demonstrated Superiority Versus HUMIRA® (adalimumab) for Primary Endpoint in a Head-to-Head Study in Rheumatoid Arthritis Patients Who Have Failed First TNF Inhibitor
recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2022 update. Ann Rheum Dis. 2023;82(1):3-18. doi:10.1136/ard-2022-223356 Khader Y, Beran A, Ghazaleh S, Lee-Smith W, Altorok N. Predictors of remission
More news about: AbbVie
Oct 13, 2025, 10:57 ET U.S. Food and Drug Administration (FDA) Approves Updated Indication Statement for RINVOQ® (upadacitinib) for the Treatment of Inflammatory Bowel Disease
Dec;12(12):720-7. doi: 10.1038/nrgastro.2015.150. Gajendran M., et al. A comprehensive review and update on ulcerative colitis. Dis Mon. 2019 Dec;65(12):100851. doi: 10.1016/j.disamonth.2019.02.004. Epub 2019 Mar 2. RINVOQ [Package Insert]. North Chicago,
More news about: AbbVie
Oct 13, 2025, 10:17 ET Boehringer and Click Therapeutics present pivotal data for investigational prescription digital therapeutic CT-155 showing a statistically significant reduction in negative symptoms of schizophrenia
Correll CU, Schooler NR. Negative symptoms in schizophrenia: A review and clinical guide for recognition, assessment, and treatment. Neuropsychiatr Dis Treat. 2020;16:519–534. A Prospective Cohort Study to Assess Clinical Effectiveness of an Investigational Digital Therapeutic
More news about: Boehringer Ingelheim Pharmaceuticals, Inc.; Click Therapeutics
Oct 13, 2025, 07:00 ET Results published in Neurology highlight a 95% reduction in risk of death with pyrimidine nucleos(t)ide therapy in patients with thymidine kinase 2 deficiency (TK2d)
Berardo A, et al. Advances in Thymidine Kinase 2 Deficiency: Clinical Aspects, Translational Progress, and Emerging Therapies. J Neuromuscul Dis. 2022;9(2):225-35. Wang J, et al. TK2-Related Mitochondrial DNA Maintenance Defect, Myopathic Form. 2018. In: Adam MP, et
More news about: UCB
Oct 10, 2025, 06:14 ET GOVWARE 2025: MENUJU BABAK BARU KEPERCAYAAN DIGITAL, INOVASI, DAN RESILIENSI
dari sejumlah lembaga seperti Cyber Security Agency (CSA), Centre for Strategic Infocomm Technologies (CSIT), the Digital and Intelligence Service (DIS), Government Technology Agency of Singapore (GovTech Singapore), dan Infocomm Media Development Authority (IMDA). GovWare juga
More news about: Image Engine Pte Ltd
Oct 09, 2025, 06:50 ET BD Reaches Major Milestone for Rotarex™ Catheter System with First Patient Enrolled in XTRACT™ Registry to Advance Real-World Evidence in Peripheral Artery Disease
1 Yost M. The current U.S. prevalence of peripheral arterial disease. Vasc Dis Manag. 2023;20(4): E67-E73.2 Allison MA, Armstrong DG, Goodney PP, et al. Health disparities in peripheral artery disease: A
More news about: BD (Becton, Dickinson and Company)
Oct 08, 2025, 15:09 ET Yeni Küresel Güzellik ve Refah Raporu Duygusal Refahın Güzelliğin Gerçek Yüzü Olduğunu Ortaya Koyuyor
iç hem de dış niteliklerle ilişkilendirmiştir. "İyi görünmek beni mutlu ediyor" refahı artırma konusunda ilk sırada yer alırken, diğer faydalar arasında "hayat hakkında daha olumlu hissetmek", "iyi göründüklerinde iç huzuru bulmak" ve "dış görünüşlerine
More news about: Oriflame
Oct 06, 2025, 08:00 ET RedHill Biopharma Signs New $1.8 Million Plus Sales Royalties Middle East Deal For Talicia®
(SEER). 15 Malfertheiner, P., Camargo, M.C., El-Omar, E. et al. Helicobacter pylori infection. Nat Rev Dis Primers 9, 19 (2023). https://doi.org/10.1038/s41572-023-00431-8
More news about: RedHill Biopharma Ltd.